Abemaciclib Improves PFS for HR+/HER2- Advanced Breast Cancer
The addition of abemaciclib to anastrozole or letrozole reduced the risk of progression or death by 46% compared with the non-steroidal aromatase inhibitors alone for previously untreated patients with HER2-negative, HR-positive advanced breast cancer.
Immune System Priming Prior to Checkpoint Blockade Improves Response in Metastatic TNBC
Turning a nonimmunogenic (“cold”) tumor into an immunogenic (“hot”) tumor appears feasible in patients with metastatic triple negative breast cancer, thereby improving sensitivity to immune therapy with nivolumab.
Dr. Palmerini on Long-term Efficacy of Denosumab in Giant Cell Tumor of Bone
September 9th 2017Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Rizzoli Orthopaedic Institute, discusses the long-term efficacy of denosumab (Xgeva) in patients with giant cell tumor of bone.
Nivolumab Past One Year Improves Progression-Free Survival in Pretreated NSCLC
Continuous treatment with nivolumab until disease progression was associated with superior progression-free survival compared with a 1-year fixed duration treatment for patients with previously treated advanced non-small cell lung cancer.
Durvalumab "Game-Changer" for Locally Advanced Lung Cancer
The PD-L1 inhibitor durvalumab improved median progression-free survival by 11.2 months compared with placebo for patients with locally advanced, unresectable stage III lung cancer who had not progressed following chemoradiotherapy.
Frontline Osimertinib Doubles PFS for EGFR+ NSCLC
Frontline osimertinib improved median progression-free survival by 18.9 months, representing a 54% reduction in the risk of progression or death compared with standard therapy for patients with EGFR-mutant non–small cell lung caner.
Taselisib, Letrozole Combination Active for ER+, HER2- Early Breast Cancer
September 8th 2017Taselisib added to standard letrozole (Femara) improved the objective response rate compared to letrozole with a placebo in postmenopausal women with estrogen receptor-positive and HER2-negative early breast cancer.
Alectinib Highly Effective for ALK+ NSCLC With CNS Metastases
Treatment with alectinib (Alecensa) demonstrated promising efficacy for patients with ALK-translocated non–small cell lung cancer with central nervous system metastases in both the first- and second-line setting.
Maintenance Rucaparib Highly Effective Across Ovarian Cancer Subtypes
Maintenance treatment with the PARP inhibitor rucaparib improved median progression-free survival by 11.2 months compared with placebo for patients with BRCA-mutant platinum-sensitive ovarian cancer.
Dr. Choueiri on Ongoing Trials of Immunotherapy in RCC
October 20th 2016Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma.
Controversy Remains on Addition of VEGF Inhibition Before Interval Debulking in Ovarian Cancer
The addition of bevacizumab to neoadjuvant platinum-based chemotherapy led to a significantly increased rate of complete resection at interval debulking in advanced ovarian cancer.
Dr. Jasgit Sachdev on Antibody-Drug Conjugate PF-06647020 in Ovarian Cancer
October 18th 2016Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a phase I study of PF-06647020, an antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in patients with platinum-resistant ovarian cancer.
Dr. Hortobagyi on MONALEESA-2 Trial Results in HR+ Breast Cancer
October 18th 2016Gabriel N. Hortobagyi, MD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses findings from the phase III MONALEESA-2 trial, which looked at the addition of the CDK 4/6 inhibitor ribociclib to endocrine therapy in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.
Dr. Jean-Yves Blay on Eribulin in Leiomyosarcoma
October 18th 2016Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.
Adding Bone Drugs to Radium-223 May Enhance Benefit in mCRPC
Men with bone-metastatic castration-resistant prostate cancer appeared to derive additional benefits from treatment with radium-223 with concomitant bone-targeted therapies, according to data from an extended-access program.